Chronic Myelogenous Leukemia Therapeutics Market by Treatment Type, Distribution Channel - Global Forecast 2025-2030- Product Image

Sale

Chronic Myelogenous Leukemia Therapeutics Market by Treatment Type, Distribution Channel - Global Forecast 2025-2030

Report
186 Pages
October 2024
Region: Global
360iResearch™
ID: 6010863

UP TO €684EUR$697USD£571GBP OFF until Dec 31^st 2024

The Chronic Myelogenous Leukemia Therapeutics Market grew from USD 7.70 billion in 2023 to USD 8.27 billion in 2024. It is expected to continue growing at a CAGR of 7.70%, reaching USD 12.95 billion by 2030.

The Chronic Myelogenous Leukemia (CML) therapeutics market involves the research, development, and commercialization of drugs and therapies aimed at managing and potentially curing this type of cancer. CML is characterized by an overproduction of white blood cells and is typically driven by the BCR-ABL gene mutation. The necessity of advancing CML therapeutics stems from the critical need to enhance patient outcomes given the chronic nature of the disease. Applications include targeted therapies like tyrosine kinase inhibitors (TKIs), bone marrow transplantation, and emerging gene therapies. End-use encompasses hospitals, specialty clinics, and other healthcare facilities providing cancer care. Key growth factors influencing this market are increasing global prevalence, rising awareness, and advancements in personalized medicine and biotechnology. Moreover, stronger healthcare infrastructure in emerging economies presents potential opportunities. Recent developments such as next-generation TKIs and improved genetic profiling foster deeper market penetration and diversification. To capitalize on these opportunities, companies should invest in R&D for next-gen therapies and expand collaborations with research institutions. However, market growth faces limitations from high treatment costs, adverse side effects, and access disparities, particularly in developing regions. Regulatory challenges and the ongoing need for comprehensive clinical trials also pose significant hurdles. Nonetheless, areas ripe for innovation include the development of therapies with an improved safety profile, novel approaches to resistance mechanisms, and advances in precision medicine to tailor treatments to individual genetic profiles. As the market grows, maintaining an agile approach to regulatory compliance will be crucial. The nature of the CML therapeutics market is dynamic and highly competitive, driven by ongoing innovation and the urgency to respond to patient needs, presenting ample opportunities for businesses to lead in impactful and sustainable ways.

Understanding Market Dynamics in the Chronic Myelogenous Leukemia Therapeutics Market

The Chronic Myelogenous Leukemia Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing number of diagnostic tests and predictive markers
- Growing prevalence of chronic myelogenous leukemia
- Rising awareness programs regarding chronic myeloid leukemia
Market Restraints
- High cost of chronic myeloid leukemia treatment drugs
Market Opportunities
- Increasing research and development activities for chronic myeloid leukemia treatment
- Rising approval of drugs for treating chronic myelogenous leukemia
Market Challenges
- Side effects and adverse reactions of chronic myeloid leukemia treatment

Exploring Porter’s Five Forces for the Chronic Myelogenous Leukemia Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Chronic Myelogenous Leukemia Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chronic Myelogenous Leukemia Therapeutics Market

External macro-environmental factors deeply influence the performance of the Chronic Myelogenous Leukemia Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chronic Myelogenous Leukemia Therapeutics Market

The Chronic Myelogenous Leukemia Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chronic Myelogenous Leukemia Therapeutics Market

The Chronic Myelogenous Leukemia Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chronic Myelogenous Leukemia Therapeutics Market

The Chronic Myelogenous Leukemia Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Myelogenous Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amneal Pharmaceuticals LLC, Bristol Myers Squibb Company, F. Hoffmann La Roche Ltd., Ilyang Pharmaceutical Co. Ltd., Incyte Corporation, Innovent Biologics Inc., Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Myelogenous Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment Type
- Biologic Therapy
- Chemotherapy
- Targeted Therapy
  - Tyrosine Kinase Inhibitors
    - Antimetabolites
    - Asciminib
    - Bosutinib
    - Dasatinib
    - Nilotinib
    - Ponatinib
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of diagnostic tests and predictive markers
5.1.1.2. Growing prevalence of chronic myelogenous leukemia
5.1.1.3. Rising awareness programs regarding chronic myeloid leukemia
5.1.2. Restraints
5.1.2.1. High cost of chronic myeloid leukemia treatment drugs
5.1.3. Opportunities
5.1.3.1. Increasing research and development activities for chronic myeloid leukemia treatment
5.1.3.2. Rising approval of drugs for treating chronic myelogenous leukemia
5.1.4. Challenges
5.1.4.1. Side effects and adverse reactions of chronic myeloid leukemia treatment
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Type

6.1. Introduction
6.2. Biologic Therapy
6.3. Chemotherapy
6.4. Targeted Therapy
6.4.1. Tyrosine Kinase Inhibitors
6.4.1.1. Antimetabolites
6.4.1.2. Asciminib
6.4.1.3. Bosutinib
6.4.1.4. Dasatinib
6.4.1.5. Nilotinib
6.4.1.6. Ponatinib

7. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Americas Chronic Myelogenous Leukemia Therapeutics Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Chronic Myelogenous Leukemia Therapeutics Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Chronic Myelogenous Leukemia Therapeutics Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation

LIST OF FIGURES

FIGURE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ASCIMINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 39. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 43. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 61. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. CHINA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 65. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 66. INDIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 73. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. JAPAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 97. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. DENMARK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 118. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. FINLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 134. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. ITALY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. NORWAY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 150. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. POLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 153. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 154. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. QATAR CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 193. CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Chronic Myelogenous Leukemia Therapeutics market, which are profiled in this report, include:

Abbvie Inc.
Amneal Pharmaceuticals LLC
Bristol Myers Squibb Company
F. Hoffmann La Roche Ltd.
Ilyang Pharmaceutical Co. Ltd.
Incyte Corporation
Innovent Biologics Inc.
Lupin Ltd.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi S.A.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	186
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 8.27 Billion
Forecasted Market Value ( USD ) by 2030	$ 12.95 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	16

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3481EUR$3,545USD£2,904GBP €3868EUR$3,939USD£3,227GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6158EUR$6,272USD£5,138GBP €6843EUR$6,969USD£5,709GBP

Understanding Market Dynamics in the Chronic Myelogenous Leukemia Therapeutics Market

Exploring Porter’s Five Forces for the Chronic Myelogenous Leukemia Therapeutics Market

Applying PESTLE Analysis to the Chronic Myelogenous Leukemia Therapeutics Market

Analyzing Market Share in the Chronic Myelogenous Leukemia Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chronic Myelogenous Leukemia Therapeutics Market

Strategic Recommendations for Success in the Chronic Myelogenous Leukemia Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Chronic Myelogenous Leukemia - Market Insight, Epidemiology and Market Forecast - 2034

Chronic Myelogenous Leukemia Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Chronic Myelogenous Leukemia Therapeutics Market 2024-2028

Acute Myelogenous Leukemia (AML) - Pipeline Insight, 2024

Acute Myeloid Leukemia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029